Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2024 Jul 24

PMID 39048301

Authors

Bonhyang Na

Yu Jin Park

Jieun Seo

Miri Park

Jee Yeon Baek

Ji Young Lee

MinYoung Kim

Jong Gyun Ahn

Seung Tae Lee

Ji-Man Kang

Affiliations

Soon will be listed here.

Abstract

Background: Respiratory syncytial virus (RSV), a highly transmissible virus, is the leading cause of lower respiratory tract infections. We examined molecular changes in the RSV genome before and after the coronavirus disease 2019 (COVID-19) pandemic in Korea, and investigated whether drug-resistant mutations were present.

Methods: In this prospective, single-center study, RSV-positive respiratory samples were collected between September 2019 and December 2022. Long-read whole-genome sequencing (WGS) was performed, and the presence of known drug-resistant substitutions for palivizumab, nirsevimab, and suptavumab was investigated.

Results: Overall, 288 respiratory samples were collected from 276 children. WGS data were available for 133 samples (71 and 62 samples from the pre- and post-pandemic periods, respectively). All RSV-A strains (n = 56) belonged to the GA2.3.5 (ON1) genotype, whereas all RSV-B strains (n = 77) belonged to the GB5.0.5a (BA) genotype. No significant differences in genotypes were observed between the pre- and post-pandemic periods. In addition, no notable mutations related to nirsevimab or palivizumab resistance were detected in the F gene. However, the L172Q and S173L substitutions, which are known to confer resistance to suptavumab, were present in all RSV-B samples.

Conclusion: Despite the unprecedented interruption of RSV seasonality, there were no significant molecular changes in circulating RSV strains in Korea related to nirsevimab or palivizumab resistance before and after the COVID-19 pandemic. However, RSV-specific drug-resistance substitutions for suptavumab were identified.

References

Ramilo O, Rodriguez-Fernandez R, Mejias A . Respiratory Syncytial Virus Infection: Old Challenges and New Approaches. J Infect Dis. 2023; 228(1):4-7. PMC: 10474936. DOI: 10.1093/infdis/jiad010. View

Ahani B, Tuffy K, Aksyuk A, Wilkins D, Abram M, Dagan R . Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023; 14(1):4347. PMC: 10356750. DOI: 10.1038/s41467-023-40057-8. View

Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064. PMC: 7613574. DOI: 10.1016/S0140-6736(22)00478-0. View

Zhu Q, Patel N, McAuliffe J, Zhu W, Wachter L, McCarthy M . Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis. 2011; 205(4):635-8. DOI: 10.1093/infdis/jir790. View

Yun K, Choi E, Lee H . Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons (1990-2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea. Arch Virol. 2020; 165(5):1069-1077. DOI: 10.1007/s00705-020-04580-z. View

Simoes E, Forleo-Neto E, Geba G, Kamal M, Yang F, Cicirello H . Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. 2020; 73(11):e4400-e4408. PMC: 8653633. DOI: 10.1093/cid/ciaa951. View

Abu-Raya B, Vineta Paramo M, Reicherz F, Lavoie P . Why has the epidemiology of RSV changed during the COVID-19 pandemic?. EClinicalMedicine. 2023; 61:102089. PMC: 10359735. DOI: 10.1016/j.eclinm.2023.102089. View

Li W, Wang Y, Yu B, Tan Q, Zhou J, Hu J . Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China. Virus Res. 2020; 281:197937. DOI: 10.1016/j.virusres.2020.197937. View

Huh K, Jung J, Hong J, Kim M, Ahn J, Kim J . Impact of Nonpharmaceutical Interventions on the Incidence of Respiratory Infections During the Coronavirus Disease 2019 (COVID-19) Outbreak in Korea: A Nationwide Surveillance Study. Clin Infect Dis. 2020; 72(7):e184-e191. PMC: 7665442. DOI: 10.1093/cid/ciaa1682. View

10.

Hall C, Weinberg G, Iwane M, Blumkin A, Edwards K, Staat M . The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360(6):588-98. PMC: 4829966. DOI: 10.1056/NEJMoa0804877. View

11.

Yu J, Fu Y, Peng X, Zheng Y, He J . Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep. 2021; 11(1):12941. PMC: 8217232. DOI: 10.1038/s41598-021-92435-1. View

12.

Tabor D, Fernandes F, Langedijk A, Wilkins D, Lebbink R, Tovchigrechko A . Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study. J Clin Microbiol. 2020; 59(1). PMC: 7771447. DOI: 10.1128/JCM.01828-20. View

13.

Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples M, Ramilo O . Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine. 2016; 35(3):496-502. PMC: 5183505. DOI: 10.1016/j.vaccine.2016.09.026. View

14.

Kim J, Kim H, Lee M, Ahn J, Baek J, Kim M . Respiratory Syncytial Virus Outbreak Without Influenza in the Second Year of the Coronavirus Disease 2019 Pandemic: A National Sentinel Surveillance in Korea, 2021-2022 Season. J Korean Med Sci. 2022; 37(34):e258. PMC: 9424700. DOI: 10.3346/jkms.2022.37.e258. View

15.

Wilkins D, Langedijk A, Lebbink R, Morehouse C, Abram M, Ahani B . Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect Dis. 2023; 23(7):856-866. DOI: 10.1016/S1473-3099(23)00062-2. View

16.

Gueudin M, Vabret A, Petitjean J, Gouarin S, Brouard J, Freymuth F . Quantitation of respiratory syncytial virus RNA in nasal aspirates of children by real-time RT-PCR assay. J Virol Methods. 2003; 109(1):39-45. PMC: 7119593. DOI: 10.1016/s0166-0934(03)00042-9. View

17.

Eden J, Sikazwe C, Xie R, Deng Y, Sullivan S, Michie A . Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun. 2022; 13(1):2884. PMC: 9130497. DOI: 10.1038/s41467-022-30485-3. View

18.

Savic M, Penders Y, Shi T, Branche A, Pircon J . Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2022; 17(1):e13031. PMC: 9835463. DOI: 10.1111/irv.13031. View

19.

Drummond A, Suchard M, Xie D, Rambaut A . Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol. 2012; 29(8):1969-73. PMC: 3408070. DOI: 10.1093/molbev/mss075. View

20.

Kim H, Hwang J, Yoon S, Lim C, Cho Y, Lee C . Molecular characterization of human respiratory syncytial virus in Seoul, South Korea, during 10 consecutive years, 2010-2019. PLoS One. 2023; 18(4):e0283873. PMC: 10079039. DOI: 10.1371/journal.pone.0283873. View